Xintela AB
The answer first
Does Xintela beat the market?
No, Xintela has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 3% of Nordic stocks
- Quality44
- Value0
- Trend9
No. 182 of 195 in healthcare
Max for seven days
Follow Xintela with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Xintela
Your first answer is free, no account needed.
Do you own Xintela, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Xintela and a few more. Free, no card.
Super Stock+44.6%In short
- Xintela has fallen 45.2% over the past year, including dividends.
- Overall, Xintela ranks better than 3% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 88.8%. The price is 97.0% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 3% of Nordic stocks.
No. 182 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 140 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−1.10
- Asset turnoverSales divided by everything the company owns0.09
- Return on equityProfit divided by equity−175.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 196 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales38.7
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 158 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−23.4%
- 6 months−45.2%
- 9 months−47.8%
- 12 months−45.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Xintela
One fund we follow owns Xintela. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Xintela
Xintela AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.


See the full analysis of Xintela.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card